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According to WHO, the prevalence of anemia in pregnancy in Indonesia is 44.3%, it is higher than 
the worldwide prevalence (41.8%). Iron deficiency is a leading cause of anemia during pregnancy. 
Ferroportin (FPN1) is an iron exporter protein which is responsible on absorbing and releasing iron 
in order to reproduce new erythocytes. The variant of FPN1-1355 G/C in promoter region enhances 
overexpression of ferroportin and iron export, which are causing elevated cellular iron needs and 
thus leading to overexpression of soluble transferrin receptor (sTfR) while decreasing hemoglobin 
(Hb) level and erythrocyte indices. As the manifestation, iron deficiency anemia (IDA) occurs. This 
research was a case and control study aimed to analyze the frequency of FPN1-1355 G/C 
polymorphism as a risk factor of IDA in pregnant women in Indonesia. Blood samples were taken 
from 26 pregnant women with anemia and 48 without anemia. FPN1-1355 G/C polymorphism were 
determined by PCR-RFLP method while sTfR and ferritin level were measured by ELISA. 
Hemoglobin, erythocyte indices, and sTfR level were compared among genotype group, then 
analyzed by independent t-test and one way ANOVA. Pearson test was conducted to analyze 
correlation between level of hemoglobin and ferritin in pregnant women (p<0.05). As the results, 
the frequency of FPN1-1355 G/C polymorphism in anemic pregnant women with IDA and non IDA 
were 100% and 95.2%, respectively (p=1.000; OR=0.800; 95%CI= 0.658-0.973). The mean of Hb 
level and erythrocyte indices in subject carrying C allele were lower than subjects carrying only G 
allele, although Hb level was not significantly different (p>0.05). The sTfR level in subject carrying 
C allele was higher than subjects carrying only G allele (p<0.05). As a conclusion, FPN1 gene 
promoter -1355 G/C polymorphism was not a risk factor for anemia, but it was a risk factor for IDA 
in pregnant women.  
Keywords: ferroportin (FPN1) -1355 G/C polymorphism, iron deficiency anemia, soluble 
transferin receptor (sTfR), ferritin. 
1. INTRODUCTION 
Iron deficiency is the most common type of anemia worldwide, affecting both developed 
and developing countries. Pregnant women are one of the vulnerable group susceptible from anemia 
due to physiologic process (WHO, 2008). Anemia in pregnant women could lead to premature 
labor, low birth weight newborn, infection, antepartum and postpartum hemorrhage, or even death 
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(Knutson, 2010; Nemeth, 2010). Prevalence of anemia in pregnancy was still high in Surakarta, 
about 53.4%, regardless of higher iron supplementation program coverage (80%) (Ministry of 
Health Republic of Indonesia, 2011). 
On iron homeostasis, ferroportin is a transporter protein coded by FPN1 gene which is 
responsible on iron distribution throughout body (Nemeth, 2010). Previous research found no 
variant or polymorphism of ferroportin Q248H gene in pregnant women population in Surakarta 
(Farmawati et al., 2012). Nevertheless, that iron transporter gene was still suspected as the cause of 
iron absorption disturbance, considering how importance ferroportin is for iron homeostasis. So this 
research aimed to analyze the polymorphism of ferroportin gene in promoter region, especially in -
1355 G/C, as a risk factor of IDA in pregnant women.  
2. RESEARCH METHODOLOGY 
An analytical case-control research was held on May 2012 to January 2013. The subjects 
were pregnant women attending Primary Health Care (PHC) in seven districts in Surakarta, Central 
Java Province, Indonesia. Samples were collected by consecutive sampling. The inclusion criterias 
were pregnant women aged 18-35 years old at 10-25 weeks of gestational age (second and third 
trimester) and willing to sign informed consent. The exclusion criterias were if subject reported 
herself had any chronic diseases (tuberculosis, diabetes mellitus, malaria, heart disease, hepatitis) 
which could interfere erythropoiesis, or had severe anemia (Hb below 7 g/dL). 
At first, 120 pregnant women were signing the informed consents, but 46 subjects were not 
eligible. Thus, measurement of Hb level (by cyanmethemoglobin method) and erythrocyte indices 
were done on 74 subjects for grouping. There were 24 subjects for anemia group (Hb <11 g/dL) and 
48 subjects for non-anemia group (Hb > 11g/dL). For specific purposes, anemia group was divided 
again into IDA group and non-IDA group based on level of Hb (<11 g/dL) and erythrocyte indices 
(mean corpuscular volume/MCV <80 fl and/or mean corpuscular hemoglobin concentration/MCHC 
<31%) (Ministry of Health Republic of Indonesia, 2011). From 26 anemia subjects, 5 were included 
in IDA group and 21 in non-IDA group.  
Deoxyribose nucleic acid (DNA) was then measured by polymerase chain reaction-
restriction fragment length polymorphism (PCR-RFLP). Ferritin level was measured by enzyme-
linked immunosorbent assay (ELISA) method using DRG® Ferritin (EIA-1872) kit, and so did 
sTfR (using Quantikine IVD® kit). Genomes of DNA were isolated from blood samples by 
Promega® isolation kit. Moreover, DNA genomes were amplified by PCR method using Master 
Mix Go Taq Green Promega® kit. PCR products were then cut off by Bfal enzyme (MBI 
Fermentas®). The electrophoresis of DNA amplifications was done in 2% agarose gel on Tris-Boric 
Acid-EDTA buffer.  
Collected data was analyzed by SPSS 19 program, a p<0.05 was considered as significant. 
The mean of of Hb, sTfR, dan ferritin between IDA group and non-IDA group were analyzed by 
independent sample t-test. The mean of Hb, sTfR, and ferritin among genotype group were 
analyzed by one-way ANOVA. Genotype frequency of each group was analyzed by one-way 
ANOVA, then the OR was determined. Correlation between level of hemoglobin and ferritin was 
analyzed by Pearson test. 
3. RESULTS 
From 74 samples, the mean age of subjects was 26,5±4.6 years old, with the youngest was 
19 and oldest was 35. The mean of gestational age was 16.4±4.2 weeks, with the minimum was 10 
weeks and maximum was 25 weeks. Subjects were divided into anemia group and non-anemia 
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group based on their Hb level. 48 subjects (61.5%) were included in non-anemia group while 26 
others were in anemia group (Table 1). Anemia group was then divided again into IDA group and 
non-IDA group based on Hb level and erythrocyte indices (Table 2).  
Table 1. Characteristic of Anemia and Non-Anemia Group 
Characteristic Value (mean±SD) p (CI 95%) Anemia (n=26) Non-anemia (n=48) 
Maternal age 
(year) 
25.923±4.454 26.604±4.676 0.545 (-2.914;1.552)* 
Gestational age 
(week) 
18.308±4.576 15.250±3.449 0.002 (1.175;4.940)* 
Notes: *independent sample t-test; SD= standard deviation; CI= confidence interval 
 
Table 2. Characteristic of IDA and Non-IDA Group 
Characteristic Value (mean±SD) p (CI 95%) IDA (n=5) Non-IDA (n=21) 
Maternal age 
(year) 
23.800±3.962 26.429±4.501 0.243 (-7.163;1.906)* 
Gestational age 
(week) 
14.600 ± 5.727 19.190±3.919 0.041 (-8.980;-0.201)* 
Hb (g/dL) 10.200±0.579 10.371±0.362 0.405 (-0.589; 0.246)* 
MCV (fL) 69.940±4.475 88.509±4.545 0.000 (-23.226;-13.913)* 
MCH (pg/sel) 22.200±2.019 29.386±1.910 0.000 (-9.166;-5.205)* 
MCHC (g/dL) 31.270±0.920 33.195±1.387 0.034 (-2.831;-0.119)* 
Note: *independent sample t-test; IDA=  iron deficiency anemia; Hb= hemoglobin; MCV= mean 
corpuscular volume, MCH= mean corpuscular hemoglobin; MCHC= mean corpuscular 
hemoglobin concentration 
Genotype investigation was done by PCR-RFLP method. The PCR product of FPN1 -1355 
gene had size of 392 bp (Picture 1), which was then cut off by Bfal enzyme. C allele (variant) 
would be 285 bp in size while G allele (wild type) would be 255 and 30 bp (Picture 2). 
 
Picture 1. PCR results of FPN1 -1355 gene, sample no. 31, 32, 33, 34, 35, 36, 37, 38, 41, 42, 43, and 44. Notes: K = 
control; M= marker; length of PCR product was 288 bp 
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Picture 2. PCR-RFLP results of FPN1 -1355 G/C, sample no. 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 
and 50. PCR products were digested by Bfal enzyme. GG genotype was showed in 255 and 30 bp band; GC in 285, 
255, and 30 bp; and CC in 285 bp. Notes: K= control; M= marker; GG= wild type; CG= mutant heterozygote; CC= 
mutant homozygote 
On this study, five pregnant women in IDA group were all having GC+CC genotype or 
carrying C allele. Meanwhile, GG genotype was not found in IDA group, so in this study C allele 
was considered as variant even though the frequency was higher than G allele. The OR of C allele 
for IDA incident was 1.600 (95%CI: 0.296-8.653) (Table 3). 
Table 3.  Genotype (CC, CG, GG) and allele (C, G) distribution of FPN1 gene promoter -
1355 in IDA and non-IDA group 
Variable IDA Non-IDA p OR (CI 95%) n=5 n=21 
Genotype CC 3 (60%) 10 (47.6%) 0.814 0.814 
CG 2 (40%) 10 (47.6%) 
  
GG 0 (0%) 1 (4.8%) 
  
GC + CC 5 (100%) 20 (95.2%) 1.000 0.800 (0.658-0.973) 
Allele C 8 (80%) 30 (71.4%) 0.710 1.600 (0.296-8.653) 
G 2 (20%) 12 (28.6%)     
The mean of Hb, MCV, MCH, and MCHC of C allele in IDA group showed lower level 
(Table 4) than non-IDA group, although Hb level was not statistically significant (p=0.401). It is 
well-known that Hb level is not a specific indicator for IDA. The mean of sTfR level in IDA group 
with C allele genotype (polymorphism) was significantly higher than non-IDA group either wild 
type (GG) or polymorphism (CG/CC) (p<0.05). Nevertheless, the mean of ferritin level was higher 
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Table 4. The mean difference of Hb, erythrocyte indices, sTfR, and ferritin between genotype groups among 
anemia subjects 
Variable 
Value (mean±SD)  
IDA (n=5) Non-IDA (n=17) 
p Wild type (n=0) Polymorphism 
(n=5) 




Hb (g/dL)  10.200±0.579 10.800 10.350±0.358 0.401* 
MCV (fL)  69.940±4.475  97.500 88.060±4.157 0.000* 
MCH (pg/cell)  22.200±2.019 33.200 29.195±1.742 0.000* 
MCHC (g/dL)  31.720±0.920 34.100 33.150±1.406 0.088* 
sTfR (nmol/L)  30.905±8.912 26.294 18.651±6.729 
(n=18) 
0.009* 
Ferritin (ng/mL)  196.167±1.17 23.250 66.048±1.17 0.045* 
Notes: *one way ANOVA; IDA= iron deficiency anemia; SD= standard deviation; Hb= hemoglobin; 
MCV= mean corpuscular volume; MCH= mean corpuscular hemoglobin; MCHC= mean 
corpuscular hemoglobin concentration; sTfR= soluble transferrin receptor 
The investigation of ferritin level described iron storage within body. The mean of ferritin 
level was 48.5±46.1 ng/mL, with the minimum level was 1.2 ng/mL and maximum was 197.9 
ng/mL. 26 subjects (63.4%) were having normal serum ferritin level (12-120 mg/mL), 9 subjects 
(22%) were low (<12 ng/mL), and 6 subjects (14.6%) were high (>120 ng/mL). It showed that most 
subjects had adequate iron storage within body. 
4. DISCUSSION 
FPN1 gene has promoter regions or transcription factor bindings (TFBs) which are 
responsible in transcriptional level of gene expression. It is known that untranslated region (5‘-
UTR) of FPN1 involves on iron homeostasis by regulating iron-responsive element (IRE). Post-
transcriptionally, iron homeostasis is controlled by iron-regulatory protein (IRP1 and IRP2). 
Meanwhile, IRPs are protein-binding RNA in cytocol. The intracellular iron level regulates several 
proteins which are involved in iron homeostasis. Iron-regulatory protein will bind the IRE in 5‘ or 
3‘ UTR of the mRNA which is coding that proteins. Both IRPs and IRE are responsible in 
connecting the sense and giving response to change the iron level within cell. It depends on where 
IRE is located, IRP binding would give the different effect on protein synthesis. From previous 
research in porphyria cutanea tarda (PCT) patients with iron metabolism disturbance, nucleotide 
transversion from G to C in 1355 position, upstreamly from ATG initiation (5‘UTR -1355 G/C), 
was found 8 (34.8%) homozygous and 13 (56.5%) heterozygous (Hallendorff, 2008). According to 
HapMap Data, frequency of polymorphic allele of 5‘UTR-FPN1-1355 G/C among Asia population 
was 10.4-16.2%. Other research mentioned that the polymorphism was 64% heterozygous in PCT 
subjects with iron metabolism disturbance (Panton, 2008). 
Normally, cellular iron would be released from reticulocytes, duodenal enterocytes, 
placenta, hepatocytes, and spleen‘s macrophages through ferroportin transporter. Macrophage 
would release iron in eryhtrocyte catabolism. Meanwhile, bone marrow would picks up circulating 
iron for erythropoiesis. This condition goes in cycle to keep the iron homeostasis. Hepcidin as  a 
regulator of ferroportin expression is stimulated by serum iron level, erythropoiesis activity, and 
inflammation (Nemeth, 2010; Pietrangelo, 2004; Cui et al., 2009). Furthermore, polymorphism of 
FPN1 could change the ferroportin expression and elevate the binding sensitivity to hepcidin. 
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Hepcidin binding on its binding-side in ferroportin surface leads to phosphorylation, internalization, 
and degradation of ferroportin by lysosome (Crichton, 2009) 
On this research, all IDA subjects were having GC+CC genotype or carrying C allele. The 
OR of C allele for IDA incidence was 1.600 (95%CI:0.296-8.653), so that we could conclude that C 
allele was a risk factor for IDA. Subjects with C allele have more risk to develop IDA, about 1.6 
times greater than G allele. C allele in FPN1 gene promoter -1355 5‘UTR is known able to raise the 
translation of FPN1 gene, thus ferroportin expression is increasing. IRE located in FPN1 gene 
5‘UTR is functional on liver, intestines, and monocytes, so it is possible to response on iron 
manipulation freely from another promoter elements. Research on human indicated that mutation on 
FPN1-IRE could evoke deregulation of cellular iron export and lead to develop certain diseases (or 
as a modification factor of fenotype expression) such as hemochromatosis and IDA (Lymboussaki 
et al., 2003). 
C allele in FPN1 -1355 G/C polymorphism generates FOXC1 transcription factor binds to 
IRE 5‘, thus inducing elevation of FPN1 gene translation (Hallendroff, 2008). Elevated ferroportin 
expression leads to raise in iron export. The increasing iron export would cause reduction of ferritin 
concentration and enhancement of cellular iron needs, thus leading to elevation of sTfR expression. 
Iron deficiency state disrupts the erythropoiesis process, and it is characterized by lower level of 
Hb, MCV, MCH, and MCHC. The statistically not significant result on allele frequency between 
IDA and non-IDA group probably occured because of the grouping method were based on Hb and 
erythrocyte indices only, which both had low sensitivity and specificity. 
Significant result was merely showed on MCV, MCH, and sTfR level among genotype of 
IDA and non-IDA group (p<0.05). It is known that erythrocyte indices, and sTfR have higher 
sensitivity and specificity than Hb level in order to diagnose IDA (Akesson et al., 1998; Wians et 
al., 2001; Lopez-Sierra et al., 2012). Moreover, lower Hb, MCV, MCH,  MCHC and higher sTfR in 
pregnant women with CG and CC genotype were in accordance with OR of C allele to IDA incident 
as high as 1.600, so that the C allele was a risk factor of IDA incidence. 
Determination of C allele as a risk factor was then confirmed by Hb, erythrocyte indices, 
serum sTfR, and ferritin level to each genotype. Measurement among 26 pregnant women with 
anemia showed that only 5 subjects were having IDA, which meant that not all of subjects in 
anemia group were having iron deficiency anemia. On iron deficiency state, there is a raise in free 
porphyrin within erythrocytes, so that the enzyme containing iron on Hb, ferrochelatase, is 
inhibited. Protein synthesis in Hb is also inhibited, but probably there is a residual chain initiation. 
Ribonucleotide reductase (RR) is a non-heme iron protein which is the most sensitive to iron 
deficiency condition, that could induce inhibition of DNA synthesis. RR inhibition by hydroxyurea 
was manifested in macrocytic anemia (DNA synthesis inhibition), not a microcytic anemia, as the 
implementation of IDA (Kell, 2009).  
Confirmation test to ferritin level revealed that most subjects had adequate iron storage. 
Nevertheless, ferritin is an acute phase protein and also a non specific iron storage indicator in 
patients with infection, inflammation, cancer, liver disease, and overactivity. If those conditions 
occur, ferritin level would raise and thus unable to measure iron storage proportionally because 
inflammation process would inhibit iron mobilization from its storage in reticuloendothelial cells 
(Kell, 2009; Lwanga, 2008; Van der Broek, 1998). Analysis found that Hb level and serum ferritin 
were having negative correlation with a very weak correlation power (r=0.064; p=0.689). This 
result meant that there will be a Hb reduction if there‘s a ferritin enhancement, vice versa. On this 
research, subjects with infection, inflammation, cancer, liver disease were not identified by specific 
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measurement during sample collection, thus the higher serum ferritin could be caused by those 
conditions. 
Ferroportin is regulated post-translationally by hepcidin, a peptide hormone. Hepcidin as a 
major iron regulator protein is responsible in regulating iron release inhibitionally by binding with 
ferroportin and enhancing both internalization and degradation of ferroportin (Knutson, 2010; Wish, 
2006). On inflammation, Kupffer cell in liver would release interleukin-6 (IL-6) which would 
increase hepcidin activity. This explains a reticuloendothelial blokage, where the iron storage 
cannot be released, represents in high serum ferritin whilst transferrin saturation is low (Wish, 
2006). There is a lot of protein involves in iron homeostasis, thus it is important to elaborate the 
pathogenesys of IDA in pregnant women. On this research, the inflammation status, ferroportin 
level, and hepcidin serum were not measured, so those factors could interfere the result of this 
research. 
This research explained that the genetic variant of FPN1 -1355 G/C in pregnant women did 
not increase the risk of anemia generally, but IDA specifically, which was reflected in low Hb and 
erythrocyte indices whilst sTfR level was high. Nevertheless, iron deficiency mentioned above was 
described as depletion of iron level for erythropoiesis or iron transportation disorder, despite the 
adequate iron storage (ferritin). This explanation was in accordance with the negative correlation 
results, reflected that the erythropoiesis disorder mentioned was not caused by low iron intake but 
iron export disturbance. 
The higher non-IDA prevalence (80%) in pregnant women more than IDA (20%) found on 
this research revealed that the pathogenesys of anemia during pregnancy was more complex than an 
ineffective erythropoiesis caused by either iron or folat deficiency. Pregnancy state could elevate 
oxidative stress that could release proinflammatory cytokines such as interleukin-6 (IL-6), 
interleukin-1 (IL-1), gamma interferon (IF-γ), and alpha tumor necrosis factor (TNF-α). Those 
cytokines could activate janus kinase/signal transducer and activator of transcription pathway (JAK-
STAT) so that the hepcidin synthesis is increasing. Hepcidin would inhibit the release of iron from 
macrophageal systems, thus leading to hypoferemia and iron restriction for erythropoiesis. This 
explains inflammation anemia, not IDA (Mackenzie et al., 2008; Ferrucci et al., 2010; Ganz et al., 
2008; Jason et al., 2001). Therefore, it is important to re-evaluate iron supplementation program for 
pregnant women since giving iron supplement for non-IDA pregnant women could lead to insulin 
resistance and cause metabolic syndrome (Bo et al., 2009; Bowers et al., 2011). 
5. CONCLUSIONS  
Polymorphism of ferroportin gene promoter -1355 G/C was not a risk factor of all anemia in 
pregnancy, but it was specific for iron deficiency anemia. It was proven by low Hb level and 
erythocyte indices followed by high sTfR level among pregnant women with C allele variant. This 
variant caused iron export disturbance which led to IDA. Iron storage was not disturbed since there 
was no significant correlation between Hb and ferritin level. 
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